在复发性复发性多发性硬化症患者中,使用贝塔干扰素和残疾进展之间的关联
Afsaneh Shirani1, Yinshan Zhao, Mohammad Ehsanul Karim
1Division of Neurology and Brain Research Centre, Department of Medicine and Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, Canada.
JAMA
|July 17, 2012
概括
在复发性复发性多发性硬化症 (MS) 患者中,干扰素β治疗没有显著改变残疾进展. 这项研究没有发现任何证据表明,白色干扰素可以降低持续扩大残疾状态量表得分为6的危险性.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 临床研究 临床研究
背景情况:
- 干扰素β是一种常见的治疗多发性硬化症 (MS).
- 它对MS中残疾进展的影响尚不清楚.
研究的目的:
- 检查干扰素β治疗与复发性复发性多发性硬化症患者的残疾进展之间的关联.
- 为了比较治疗患者的结果与当代和历史未经治疗的队列.
主要方法:
- 使用从不列颠哥伦比亚省 (1985-2008) 收集的前性数据进行了回顾性队列研究.
- 与不接受治疗的当代 (n=829) 和历史 (n=959) 队列的干扰素β治疗患者 (n=868) 的比较.
- 使用扩展残疾状况尺度 (EDSS) 来测量残疾进展和考克斯回归,并进行倾向得分调整.
主要成果:
- 与当代 (HR 1.30,P=.14) 或历史 (HR 0.77,P=.07) 对照相比,对干扰素β暴露在达到持续EDSS得分6的危险性上没有统计学上显著的差异.
- 达到EDSS 6的观察结果率为10.8% (接受治疗),5.3% (当代) 和23.1% (历史).
- 对混因子和倾向分数的调整没有改变这些发现.
结论:
- 在复发性复发性多发性硬化症患者中,贝塔干扰素的使用与残疾进展率的降低无关.
- 这些发现表明,干扰素β可能无法有效地减缓该患者群体中残疾累积的速度.
更多相关视频
10:00High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
13.6K
10:46A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
10.3K
相关概念视频
01:30Inhibitors of Viral Protein Synthesis
73
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
73
01:19Multiple Sclerosis l: Introduction
31
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
31